Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumafantrine vs chloroquine + sulfadoxine-pyrimethamine-Centers for Disease Control and Prevention-malaria (Plasmodium falciparum)
- Development stage
- Unknown
- Lead developer
- Centers for Disease Control and Prevention
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a comparative clinical trial intervention evaluated by the Centers for Disease Control and Prevention (CDC) for the treatment of uncomplicated *Plasmodium falciparum* malaria. The study (NCT00122616) compared the efficacy of two distinct combination regimens: **artemether + lumafantrine** (an artemisinin-based combination therapy or ACT) and **chloroquine + sulfadoxine-pyrimethamine**. Artemether is a fast-acting artemisinin derivative that rapidly reduces parasite burden by inhibiting the parasite's calcium ATPase, while lumefantrine is a long-acting aryl amino alcohol that clears residual parasites by interfering with heme detoxification. Chloroquine is a traditional 4-aminoquinoline that also inhibits heme polymerization. Sulfadoxine and pyrimethamine work synergistically as antifolates, inhibiting dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), respectively, to block parasite DNA synthesis. The trial was conducted in the Philippines to assess the therapeutic efficacy and potential for drug resistance in the region.
- Brand names
- CoartemFansidar
- Other names
- artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamineAL vs CQ+SPEfficacy of CQ+SP vs Artemether-Lumefantrine for Malaria in Philippines
02
Targets
PfATP6 (Plasmodium falciparum ATP6)DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)β-Hematin
Beyond the preview
Go deeper on artemether + lumafantrine vs chloroquine + sulfadoxine-pyrimethamine-Centers for Disease Control and Prevention-malaria (Plasmodium falciparum).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumafantrine vs chloroquine + sulfadoxine-pyrimethamine-Centers for Disease Control and Prevention-malaria (Plasmodium falciparum).